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Abstract 
 Inducing the innate human immune system’s host defense peptide activity presents a 
novel alternative for antimicrobial therapy in the fight against antibiotic-resistant bacterial 
strains. The human body has only one cathelicidin host defense peptide, known as LL-37. The 
compound butyrate has already been identified as a positive control for inducing LL-37 gene 
expression, however a high-throughput screening assay has identified several additional potential 
compounds as possible host defense peptide inducing compounds in animal cell lines. This study 
investigates the efficacy of LL-37 induction for three structurally similar histone deacetylase 
inhibiting compounds, Mocetinostat, Chidamide, and Entinostat in an in vitro study utilizing the 
human HT-29 cell line. Total RNA isolation and REAL Time PCR amplification techniques 
were used to identify relative fold-change in gene expression. All three compounds exhibited 
significant fold-increase in LL-37 gene expression, with Mocetinostat demonstrating the highest 
efficacy out of the three compounds. The results of this investigation confirm previous findings 
and provide a basis for future time course and in vivo investigations on the path to utilizing the 
innate human immune system as a possible novel alternative to antibiotics.  
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Introduction 
Antibiotic resistance is an alarming problem that has been puzzling the medical 
community for years. While scientists are always working to develop more effective antibiotics, 
pathogenic bacterial strands continually adapt more quickly than medical developments, 
resulting in several deaths each year. The solution to this problem may not lie in a stronger 
antibiotic, but in a novel approach to antimicrobial therapy. Host-defense peptides (HDP) are a 
component of the innate immune system in mammals whose primary role is a rapid and broad 
antimicrobial response when the body is exposed to pathogens.  
The human body contains only one cathelicidin antimicrobial peptide (CAMP) or more 
commonly known by the encoding gene, LL-37. This peptide is extremely small, with a chain of 
only 37 amino acids in its active form1. The peptide is amphipathic and positively charged for 
rapid transport through the body. It utilizes its positive charge allows to quickly attract to and 
bind to pathogens, such as negatively-charged bacteria2. The peptide utilizes those electrostatic 
interactions with the bacterial membrane to disrupt it completely and eliminate its pathogenic 
potential3. LL-37 has shown to be effective against gram-negative bacteria, gram-positive 
bacteria, fungi, and even some parasitic pathogens2. LL-37 is transcriptionally regulated by 
histone deacetylase activity, and studies have already proven a direct correlation between 
decreased histone deacetylase activity and increased LL-37 expression2.  By inducing activity of 
this peptide, it is possible that in the future induction of the body’s innate immune response 
could be used to respond to bacterial infections typically treated with prescription antibiotics.  
 In this cell-line, dosage-response study, human HT-29 cells were induced with three 
compounds at varying concentrations to test their efficacy in inducing a fold-increase in LL-37 
gene expression, and thus LL-37 peptide activity. These drugs had already been targeted in a 
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high-throughput screening process as potential host-defense peptide inducing compounds and 
have been experimentally proven to induce host-defense peptide expression in chicken cell 
lines4. Human HT-29 cells are colon epithelial cells and were selected because of their ability to 
mimic in vivo responses and because of their high replication rate4. Additionally, LL-37 
naturally exhibits a majority of its antimicrobial activity in the intestinal lining of human body 
due to high concentrations of pathogens4, making HT-29 cells the most ideal cell line for in vitro 
investigations. Butyrate and its analogs have already been identified and proven for inducing a 
wide variety of host-defense peptide expression5, therefore it was used as the positive control for 
this investigation as a means of comparison for test compound efficacy. Similar or greater fold 
increase than butyrate could indicate a more effective compound at inducing LL-37 expression.  
Mocetinostat, Chidamide, and Entinostat were the test compounds used in this 
investigation that had been previously identified through high-throughput screening. All of these 
compounds are histone deacetylase inhibitors6, 7, 8, meaning they could potentially inhibit the 
activity of the LL-37 transcriptional regulator and allow increased fold-change expression of the 
gene. Mocetinostat and Chidamide have been identified as potential compounds in cancer 
research for decreasing activity of immune suppressive cells and allowing for increased immune 
response against cancer cell types6, 7. Entinostat has been identified in preliminary studies to up-
regulate LL-37 expression through both histone-deacetylase inhibition, and more specifically by 
activation of transcription factor STAT3 as outlined in the Miraglia et. al. study. Additionally, 
Entinostat has been proven to exhibit antimicrobial activity against cholera bacteria9, specifically 
linking increased LL-37 regulation and expression, with antimicrobial peptide activity making 
the compound an ideal compound not only for this investigation, but as a potential novel 
alternative to antibiotics.   
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Methodology 
Identification of induced activity of host defense peptides is most easily noted by the 
measurement of fold increase in LL-37 gene expression. Methods for identifying gene 
expression involved treating cells with selected compounds, isolating and purifying RNA, and 
amplifying complementary cDNA strands through REAL Time PCR to obtain fold increase.  
Cell Culture and Treatment 
Following cell maintenance protocol outlined in Jiang et al.5, human HT-29 cells were 
grown in 1640 RPMI medium with 10% FBS serum solution and 1% penicillin/streptomycin 
antibiotic concentration (2013). Cells were incubated at 37ºC and subcultured every four to five 
days to maintain viability. Subculturing was done using 1640 RMPI medium and Trypsin 
enzyme for cell dislodgement. Cells were seeded into 12-well plates at 2.5x105 cells per well in 
order to optimize cell growth during treatment. After seeding, cells were returned to 37ºC 
incubation for adaption and growth for 24 hours before treatment. Cells were treated on a 
dosage-response regimen with the compounds and concentrations outlined in Figure 1. Control 
wells received no additional compounds at the time of stimulation. Cells were lysed 24 hours 
after treatment as this was identified as the ideal time course for LL-37 inducing efficacy for 
Entinostat in the Miraglia et al. investigation8.  
 
Control 1 Control 2 5uM Mocetinostat 5uM Mocetinostat 
2uM Butyrate 2 uM Butyrate 10uM Mocetinostat 10uM Mocetinostat 
2uM Mocetinostat 2uM Mocetinostat 20uM Mocetinostat 20uM Mocetinostat 
 
 





Total RNA Isolation 
Cells were harvested with 250ul of RNAzol per well. DNA was removed and RNA was 
purified through multiple ethanol washes and centrifugations at 4ºC. Isolated RNA was 
solubilized in RNAse free H2O at 55ºC. The concentration of solubilized RNA was taken via 
NanoDrop and all samples were diluted to 300ng/ul. All solubilized RNA was stored at -80 ºC 
and kept on ice during procedures to maintain viability. Complimentary cDNA strands were 
generated with diluted RNA samples following the BioRad iScript Reverse Transcriptase cDNA 
synthesis kit protocol. 
REAL Time PCR and Statistical Analysis 
cDNA samples were amplified utilizing SYBR-based REAL Time PCR targeting LL-37 
gene expression. △△ Ct mean calculations revealed relative fold increase in gene expression of 
LL-37 in reference to human actin beta gene and a negative control. The experiment was 
repeated three times to confirm results and reduce the impact of human error. One-way ANOVA 
and post hoc Tukey’s test were used to determine statistical significance. All results had a p 
value < 0.05, which was the marker used for determining significance of results.    
5uM Chidamide 5uM Chidamide 5uM Entinostat 5uM Entinostat 
10uM Chidamide 10uM Chidamide 10uM Entinostat 10uM Entinostat 
20uM Chidamide 20uM Chidamide 20uM Entinostat 20uM Entinostat 
Figure 1: Treatment compounds used to stimulate HT-29 cells in 12-well plates. The 
first two trials tested 40uM Mocetinostat in replacement of 2uM Mocetinostat after 
high concentration of Mocetinostat demonstrated low efficacy.  
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Results 
 Relative-fold increase expression of LL-37 in HT-29 is summarized below for 
Mocetinostat, Chidamide, and Entinostat in comparison to their relative control. The results are 
means + standard errors of three independent trials with **P < 0.01, ***P <0.001, ****P < 
0.0001, relative to the control by Tukey’s test. Results for known positive control butyrate are 
not outlined in this report, however fold-increase for those samples were confirmed as expected 
in comparison from previous investigations5.  
  
Figure 3: LL-37 fold change in HT-29 cells treated with 
2uM to 40uM of Mocetinostat in a 24 hour period.  
 
Figure 2: Chemical structures of the three test compound 
used in this investigation 














Figure 5: LL-37 fold change in HT-29 cells treated with 
2uM to 20uM of Chidamide in a 24 hour period.  
 
Figure 4: LL-37 fold change in HT-29 cells treated with 
2uM to 20uM of Entinostat in a 24 hour period.  
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Conclusions 
 All test compounds demonstrated significant fold-increase expression of the LL-37 gene 
after normalization to a reference gene (hACTB) and relative comparison to negative-control 
groups. During the first two trials, Mocetinostat concentration was tested at 5uM, 10uM, 20uM, 
and 40uM however lack of efficacy at 40uM prompted the investigation of a lower concentration 
dosage, with the final two trials investigating 2uM, 5uM, 10uM, and 20uM. A negative 
correlation between HDP induction and Mocetinostat concentration clearly exists, with highest 
efficacy at 2uM Mocetinostat concentration. 
 Chidamide exhibits similar correlation between concentration and efficacy, with the 
highest efficacy at 5uM. Entinostat demonstrated a positive correlation between concentration 
and efficacy of the compound to induce fold change, with the highest fold change expression at 
20uM. Entinostat treated cells, however, did show lowest data precision in comparison to the 
other compounds. Mocetinostat exhibited the highest fold-change out of all the compounds at 
2uM concentration.  
Discussion 
 The results of this investigation confirmed that Mocetinostat, Chidamide, and Entinostat 
all induce LL-37 gene expression. With different dosage-response trends, further investigations 
can identify both lower concentrations (Figure 3, 5) or higher concentrations (Figure 4) to 
determine if more effective dosage responses exist beyond the scope of this study. Additionally, 
further cell-line studies can take ideal dosage concentrations to determine ideal treatment time 
through time-course studies beyond that outlined in current literature.  
As the most effective compound, Mocetinostat (Figure 3) should be further analyzed as 
novel alternative to antibiotics. In addition to dosage-response and time course treatments, this 
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compound should be tested for its induction of inflammation gene expression in addition to its 
expression of LL-37. Inflammation response is the biggest concern of inducing the innate 
immune system and overactive inflammation response can cause more harm than benefit. Future 
studies should focus on known immune system inflammation gene activity alongside LL-37 gene 
expression. Additionally, looking into the enzyme-substrate relationship between the test 
compounds and histone deacetylase could provide insight into how that relationship can be 
further manipulated via inhibition or allosteric regulation to allow increased expression of LL-
37. Further investigations into the regulation of LL-37 beyond histone deacetylation could 
provide additional ways to manipulate regulatory mechanisms for inducing LL-37 expression.  
Once ideal dosage, time, and coupled compounds for controlled inflammation response 
have been identified, this study should move into in vivo trials. Animal trials have already begun 
for investigation of host-defense peptide inducing compounds in both chicken and porcine 
subjects and have demonstrated positive results4. The demand for antibiotic-free livestock and a 
more effective antimicrobial therapy in human pharmaceuticals creates a unique opportunity for 
enhanced cooperation between animal and human medicine to maximize resources and funding 
for continuing the investigation of identification of a novel alternative to antibiotics. Animal 
trials in mice would serve as the precursor to human clinical trials and help determine the proper 
conditions for optimal in vivo induction. 
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